person working in the lab

Shaping the Forefront of Cancer Care Together

We can support you from initial discovery to launch of a new therapy with our global portfolio of tests and services and our scientific and regulatory experts to fit your specific needs.

Experience Brings Ease and Efficiency

As a leader in companion diagnostic (CDx) approvals, we are your ideal partner to help make your next breakthrough a standard of care.

Biopharmaceutical Solutions


Our proven portfolio of high-quality comprehensive tests and our regulatory-ready dataset can accelerate clinical trial enrollment, inform trial design, or create new insights from your banked samples to discover biomarkers, identify resistance, or determine which patients could benefit from your therapy.

Liquid CDx and Tissue CDx products

Our FoundationOne®CDx and FoundationOne®Liquid CDx tests have 60% of all CDx approvals for NGS testing in the United States and Japan – the most of any diagnostic company2 – and we have capabilities to develop our portfolio for the upcoming European Union In Vitro Diagnostics Regulation (EU IVDR).


We provide broad access to precision medicine around the world, with our tests available in more than 100 countries, and offer flexible solutions to accelerate your commercial launch, such as our alert service to provide timely, de-identified alerts on biomarker populations to support marketing and sales effectiveness.

Proven Leadership for Biopharma & Research Partners


Patient Reports Delivered Globally


of all US CDx approvals for NGS testing*


Patients in Our Clinico-Genomic Database (CGDB)

Need More Details? 

We are here to help. Contact our Biopharma Team for more information. 

Contact Us

1. Reichert et al. Annals of Oncology 2022. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study

2. Data on file, Foundation Medicine, Inc., data as of Nov. 18, 2022.

* Data on file, Foundation Medicine Inc., data as of Nov. 18, 2022.

Important Safety Information


FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit